Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study being conducted at multiple centers in the United States. Patients
having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are
eligible to participate. Patients must have disease that was not controlled by previous
treatment with radioactive iodine (131I) or not be good candidates for such treatment. The
purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective
treatment for metastatic thyroid cancer as shown by the number of patients in the study who
experience significant and durable tumor shrinkage.